Our pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and we have multiple clinical trials underway with other development candidates progressing toward the clinic. Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform, the infrastructure to accelerate drug discovery and early development, a rapidly expanding pipeline, and a world-class team. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. Moderna Therapeutics USA Private We are pioneering a new class of medicines made of messenger RNA, or mRNA. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. Heat Biologics USA Listed Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
OPENVIEW VENTURE PARTNERS ICONIQ 3B LUNDENTECHCRUNCH ARCHIVE
Community submitted dataĪssociated sectors: Life Sciences Biologics Healthtech SARS-CoV-2 Vaccine Cancer Melanoma Immunotherapy Diagnostics DNA RNA Peptide Therapies Vaccines Biotech Website archive shows the site was first archived on 2016.ĬureVac Germany Private CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. We work directly with corporations and also with service providers (such as open innovation agencies, outsourced R&D consultants, and traditional crowd-sourcing companies) to provide them with our intelligent company discovery capabilities. By structuring and analysing this information we are able to accurately match our clients needs with the start-ups, SMEs and other innovators that have the skills our clients need. We discover innovative companies from across the globe using our Company Discovery Engine, which trawls the web to harvest and aggregate company information at a scale, speed and efficiency that hasn’t previously been possible. VentureRadar helps organisations innovate and generate new growth by connecting them to the emerging technologies and expertise that can solve their challenges.
0 kommentar(er)
